Tango Therapeutics (TNGX) Return on Equity (2021 - 2025)
Historic Return on Equity for Tango Therapeutics (TNGX) over the last 5 years, with Q3 2025 value amounting to 0.68%.
- Tango Therapeutics' Return on Equity fell 1600.0% to 0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68%, marking a year-over-year decrease of 1600.0%. This contributed to the annual value of 0.58% for FY2024, which is 1700.0% down from last year.
- Per Tango Therapeutics' latest filing, its Return on Equity stood at 0.68% for Q3 2025, which was down 1600.0% from 0.96% recorded in Q2 2025.
- Tango Therapeutics' Return on Equity's 5-year high stood at 0.16% during Q4 2021, with a 5-year trough of 8.7% in Q2 2021.
- Its 5-year average for Return on Equity is 0.96%, with a median of 0.45% in 2024.
- Per our database at Business Quant, Tango Therapeutics' Return on Equity skyrocketed by 84100bps in 2022 and then plummeted by -5100bps in 2025.
- Tango Therapeutics' Return on Equity (Quarter) stood at 0.16% in 2021, then crashed by -153bps to 0.41% in 2022, then increased by 7bps to 0.38% in 2023, then crashed by -58bps to 0.61% in 2024, then fell by -12bps to 0.68% in 2025.
- Its Return on Equity was 0.68% in Q3 2025, compared to 0.96% in Q2 2025 and 0.72% in Q1 2025.